Search For "controller"
Serum Institute initiates phase 2, 3 clinical study on 1,600 volunteers fo
Updated : 5 years, 7 months ago IST
New Delhi [India], August 19 (ANI): Indian pharmaceutical giant Serum Institute of India has initiated the phase 2, 3 clinical trials to evaluate the safety and immune response of coronavirus vaccine candidate on healthy Indian adults after the pharma company got approval from Drugs Controll
Read More
Dr Reddy's launches Avigan (Favipiravir) for COVID-19 treatment
Updated : 5 years, 7 months ago IST
Hyderabad (Telangana) [India], Aug 19 (ANI): Dr Reddy's Laboratories on Wednesday announced the launch of Avigan (Favipiravir) 200 mg tablets in India for treatment of patients with mild to moderate COVID-19 disease.
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 per table
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More
DGCI nod for Apheresis machine to extract blood plasma in Goa
Updated : 5 years, 7 months ago IST
Panaji (Goa) [India], Aug 4 (ANI): Goa has made a new breakthrough in its plasma therapy for critically ill COVID-19 patients after Drugs Controller General of India (DGCI) gave its approval for using Apheresis machine to extract blood plasma, said Health Minister Vishwajit P Rane.
Read More
DCGI gives nod to Serum Institute to hold Phase II, III COVID vaccine tria
Updated : 5 years, 7 months ago IST
New Delhi [India], Aug 3 (ANI): The Drugs Controller General of India (DCGI) gave approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India, said the Ministry of Health and Family Welfare on
Read More
DCGI nod to Serum-Oxford COVID19 vaccine for phase 2, 3 clinical trials in
Updated : 5 years, 7 months ago IST
New Delhi, [India], Aug 3 (ANI) India's top drug regulator-- Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine, a senior government official said.
Read More
COVID-19: Health Ministry directs DCGI to ensure equitable distribution of
Updated : 5 years, 7 months ago IST
New Delhi [India], July 29 (ANI): The Union Health and Family Welfare Ministry has directed the Drugs Controller General of India (DCGI) to ensure equitable distribution of drugs across the country included as part of "investigational therapies" in clinical management protocol for COVID-19.
Read More
COVID-19: Health ministry decides not to put Itolizumab in national treatm
Updated : 5 years, 7 months ago IST
New Delhi, July 26 (ANI): Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for co
Read More
Domestic pharma giant SII applies to DCGI for phase 2/3 clinical trial of
Updated : 5 years, 7 months ago IST
New Delhi [India], July 25 (ANI): In a development related to the COVID-19 vaccine, the Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) for conducting the Phase 2/3 human clinical trials for a potential coronavirus vaccine.
Read More
Cipla gets regulatory nod for launch of Ciplenza to treat mild to moderate
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Pharmaceutical major Cipla said on Friday it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza.
Read More
COVID-19: DCGI nod to Jubilant Generics to manufacture, sell remdesivir f
Updated : 5 years, 8 months ago IST
New Delhi [India], July 20 (ANI): The Drug Controller General of India (DCGI) has granted permission to pharma giant- Jubilant Generics Ltd to manufacture and market the anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, a senior health ministry offi
Read More
DCGI seeks clarification from Glenmark on its anti-viral favipiravir for u
Updated : 5 years, 8 months ago IST
New Delhi [India], July 19 (ANI): The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
Read More